11
ALL11
Yisheng BiopharmaYear
11
ALL2
20245
20232
20222
2021DEALS // DEV.
11
ALL1
Deals10
DevelopmentsCountry
11
ALL11
CHINA11
ALL10
Inapplicable1
OceanpineTherapeutic Area
11
ALL11
Infections and Infectious DiseasesStudy Phase
11
ALL1
Approved FDF4
Phase III4
Phase II/ Phase III1
Phase II1
Phase IDeal Type
11
ALL10
Inapplicable1
Series B FinancingProduct Type
11
ALL11
VaccineDosage Form
11
ALL2
Intramuscular8
Intramuscular Injection1
UndisclosedLead Product
11
ALL1
COVID-19 Vaccine Recombinant1
Inactivated Rabies Vaccine, PIKA-Adjuvanted3
PIKA COVID-19 Vaccine4
PIKA Rabies Vaccine1
YS-HBV-0021
YSJA Rabies VaccineTarget
11
ALL4
SARS-CoV-2-viral spike protein7
UndisclosedLead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma Reports Positive Interim Results from Phase 3 Study of PIKA Rabies Vaccine
Details : Vero Cell (PIKA rabies vaccine) is an intramuscularly administered freeze dried vaccine candidate, which is being evaluated for the treatment of rabies in humans.
Product Name : Vero Cell
Product Type : Vaccine
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : YS-HBV-002
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma Granted Phase I License for Therapeutic Chronic Hepatitis B Virus Vaccine
Details : YS-HBV-002 is an intramuscularly administered, immuno-therapeutic vaccine, which is being developed for the treatment of patients with Chronic Hepatitis B.
Product Name : YS-HBV-002
Product Type : Vaccine
Upfront Cash : Inapplicable
April 18, 2024
Lead Product(s) : YS-HBV-002
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The PIKA Rabies Vaccine, which utilizes YS Biopharma's proprietary PIKA adjuvant technology, is designed to produce a more robust immune response in an accelerated timespan compared to existing rabies vaccines.
Product Name : Vero Cell
Product Type : Vaccine
Upfront Cash : Inapplicable
October 31, 2023
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Vero Cell
Product Type : Vaccine
Upfront Cash : Inapplicable
September 26, 2023
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan
Details :
Product Name : Vero Cell
Product Type : Vaccine
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : PIKA Rabies Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 27, 2023
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Inactivated Rabies Vaccine, PIKA-Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 06, 2023
Lead Product(s) : Inactivated Rabies Vaccine, PIKA-Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YS Biopharma Announces US FDA Clearance Of IND Application For PIKA COVID-19 Vaccine
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 11, 2022
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : COVID-19 Vaccine Recombinant
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
YishengBio PIKA Recombinant COVID-19 Vaccine Gets Phase I Trial IND Clearance
Details :
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
July 18, 2021
Lead Product(s) : PIKA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable